Gammagard

Gammagard is an immunoglobulin-based drug manufactured by Baxter International.[1] It is a brand of intravenous immunoglobulin.[2]

Early experimental results from a small clinical trial in humans have shown hints that it may protect against the progression of Alzheimer's Disease.[2][3]

In 2013 it failed a phase III clinical trial for Alzheimer's Disease.[4]

References

  1. ↑ "Baxter's Gammagard shows potential in stabilizing Alzheimer's". The Pharma Letter. 18 July 2012. Retrieved 2012-07-19.
  2. ↑ 2.0 2.1 Andrew Pollack (July 17, 2012). "Small Trial Hints Drug Can Slow Alzheimer’s". New York Times. Retrieved 2012-07-19.
  3. ↑ "Experimental Alzheimer's drug Gammagard may stall memory decline, small study suggests". CBS News. 2012-07-17. Retrieved 2012-07-19.
  4. ↑ Another Alzheimer's Drug Fails Phase III Trial

External links